6533b7dafe1ef96bd126d874
RESEARCH PRODUCT
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies
A RussoL IncorvaiaE CapoluongoP TagliaferriS GoriL CortesiM GenuardiD TurchettiU De GiorgiM Di MaioM BarberisM DessenaM Del ReA LapiniC LuchiniB A Jereczek-fossaA SapinoS Cinieri Italian Scientific Societies Collaborators:Beretta Giordano Maria Angela BellaBracarda SergioColombo NicolettaConteduca Vincenza Lucia Del MastroGalvano AntonioGristina ValerioGuarneri Valentina Nicla La VerdeLorusso DomenicaMarchetti PaoloNormanno NicolaOttini LauraPensabene MatildePignata SandroProcopio GiuseppeRicevuto EnricoSilvestris NicolaTassone PierfrancescoTucci MarcelloDonato VittorioCarrara SilviaSalvatore PaiellaGentilini OresteGunelli RobertaNicolis FabrizioButtitta FiammaColecchia MaurizioFassan MatteoMalapelle UmbertoMarchetti AntonioMarchiò CaterinaAldo ScarpaTruini MauroGiuseppe ZamboniGion MassimoTrevisiol ChiaraGronchi AlessandroDanesi Romano Vito Di MarcoCarrera PaolaGhiorzo PaolaPasini BarbaraVaresco LilianaArtibani WalterLudovico GiuseppeCampanella OrnellaVatrano SimonaTagliafico Enricosubject
Societies ScientificMaleOvarian NeoplasmsCancer Researchgenetic counselingBRCABRCA testing; BRCA-related cancer; BRCA1; BRCA2; PARP inhibitors; genetic counseling; pancreatic ductal adenocarcinomaProstatic Neoplasmspancreatic ductal adenocarcinomaScientificSettore MED/03 - GENETICA MEDICABRCA testing; BRCA-related cancer; BRCA1; BRCA2; PARP inhibitors; genetic counseling; pancreatic ductal adenocarcinoma; Female; Humans; Italy; Male; Societies Scientific; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic NeoplasmsBRCA1BRCA2BRCA-related cancerPancreatic NeoplasmsBRCA testingPARP inhibitorOncologyItalyHumansFemaleSocietiesPARP inhibitorsdescription
Constitutional BRCA1/BRCA2 pathogenic or likely pathogenic variants (PVs) are associated with an increased risk for developing breast and ovarian cancers. Current evidence indicates that BRCA1/2 PVs are also associated with pancreatic cancer, and that BRCA2 PVs are associated with prostate cancer risk. The identification of carriers of constitutional PVs in the BRCA1/2 genes allows the implementation of individual and family prevention pathways, through validated screening programs and risk-reducing strategies. According to the relevant and increasing therapeutic predictive implications, the inclusion of BRCA testing in the routine management of patients with breast, ovarian, pancreatic and prostate cancers represent a key requirement to optimize medical or surgical therapeutic and prevention decision-making, and access to specific anticancer therapies. Therefore, accurate patient selection, the use of standardized and harmonized procedures, and adherence to homogeneous testing criteria, are essential elements to implement BRCA testing in clinical practice. This consensus position paper has been developed and approved by a multidisciplinary Expert Panel of 64 professionals on behalf of the AIOM-AIRO-AISP-ANISC-AURO-Fondazione AIOM-SIAPEC/IAP-SIBioC-SICO-SIF-SIGE-SIGU-SIU-SIURO-UROP Italian Scientific Societies, and a patient association (aBRCAdaBRA Onlus). The working group included medical, surgical and radiation oncologists, medical and molecular geneticists, clinical molecular biologists, surgical and molecular pathologists, organ specialists such as gynecologists, gastroenterologists and urologists, and pharmacologists. The manuscript is based on the expert consensus and reports the best available evidence, according to the current eligibility criteria for BRCA testing and counseling, it also harmonizes with current Italian National Guidelines and Clinical Recommendations.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2022-01-01 |